According to UroGen, UGN-102 has the potential to be the first FDA-approved treatment for low-grade, intermediate-risk, non-muscle-invasive bladder cancer.
Urogen Pharma Submits New Drug Application to FDA for UGN-102, a Potential Treatment for Low-Grade, Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Leave a comment
